CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −19,656 | $70.61 | $1.4M | 37,371 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −8,777 | $71.56 | $628K | 28,594 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −12,777 | $72.94 | $932K | 15,817 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −10,358 | $73.74 | $764K | 5,459 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −5,059 | $74.60 | $377K | 400 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −400 | $75.37 | $30K | 0 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −78,333 | 321,667 | ||
| 2026-05-01 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +12,500 | $14.50 | $181K | 110,494 |
| 2026-05-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −12,500 | $71.37 | $892K | 97,994 |
| 2026-05-01 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,500 | 382,357 | ||
| 2026-05-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −5,300 | $69.54 | $369K | 622,240 |
| 2026-05-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −3,600 | $70.77 | $255K | 618,640 |
| 2026-05-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −1,000 | $71.76 | $72K | 617,640 |
| 2026-05-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −3,100 | $73.14 | $227K | 614,540 |
| 2026-05-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −1,700 | $74.23 | $126K | 612,840 |
| 2026-05-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −300 | $74.96 | $22K | 612,540 |
| 2026-04-01 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +7,500 | $14.50 | $109K | 105,494 |
| 2026-04-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −6,200 | $49.21 | $305K | 99,294 |
| 2026-04-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −1,300 | $49.98 | $65K | 97,994 |
| 2026-04-01 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 394,857 |
Page 6 of 11 · 213 trades